期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HLA-DR15等位基因在骨髓增生异常综合征临床发生及预后中的意义 被引量：1

原文传递
导出
摘要 骨髓增生异常综合征（MDS）是一组起源于骨髓造血干/祖细胞的恶性克隆增殖性疾病,目前MDS的发病机制仍未完全清楚,研究结果显示T淋巴细胞-HLA-细胞因子免疫途径可能参与MDS一些亚型的发病[1-2].文献报道MDS患者外周血HLA-DR15表达较正常对照组增高,且表达HLADR15的难治性贫血（RA）患者对于免疫抑制剂如抗胸腺细胞球蛋白等治疗效果显著优于不表达者[3-6],提示HLADR15可能是免疫导致的骨髓衰竭的一个特异的易感因素.我们通过聚合酶链反应-序列特异性引物（PCR-SSP）技术检测MDS患者HLA-DR15等位基因的表达情况,并结合相关因素进行分析,旨在进一步探讨作为MHC-Ⅱ类分子的HLADR15在MDS病理生理学方面的意义.
作者 廖琼 李晓 张言 张征 宋陆西 徐黎 陶英 刘薏芝 浦权
机构地区 上海交通大学附属第六人民医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2011年第4期269-271,共3页 Chinese Journal of Hematology
关键词 骨髓增生异常综合征 等位基因 聚合酶链反应-序列特异性引物 恶性克隆增殖性疾病 骨髓造血干/祖细胞 抗胸腺细胞球蛋白 MHC-Ⅱ类分子 预后
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献13

  • 1Baumann I,Scheid C,Koref MS,et al.Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome.Exp Hematol,2002,30:1405-1411.
  • 2Molldrem JJ,Jiang YZ,Stetler-Stevenson M,et al.Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles.Br J Haematol,1998,102:1314-1322.
  • 3Saunthararajah Y,Nakamura R,Nam JM,et al.HLA-DR15(DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.Blood,2002,100:1570-1574.
  • 4Maciejewski JP,Follmann D,Nakamura R,et al.Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome.Blood,2001,98:3513-3519.
  • 5Saunthararajah Y,Nakamura R,Wesley R,et al.A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.Blood,2003,102:3025-3027.
  • 6Okamoto T,Okada M,Yamada S,et al.Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1 * 1501 allele.Leukemia,2000,14:344-346.
  • 7Olerp O,Zetterqueist H.HLA-DR typing by PCR-amplification with sequence primers in 2 hours:an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantion.Tissue Antigens,1992,39:225-235.
  • 8Sun JI,Du KM,Fu M,et al.Statistical analysis of HLA polymorphism among 20596 stem cell donors of Han nationality.Chin J Blood Transfusion,2006,19:379-384.
  • 9Wang RF.Identification of MHC class Ⅱ -restricted tumor antigens recognized by CD4 + T cells.Methods,2003,29:227-235.
  • 10Oka Y,Tsuboi A,Murakami M,et al.Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.Int J Hematol,2003,78:56-61.

同被引文献24

  • 1Santini V. Novel therapeutic strategies: hypomethylating agents and heyond[J]. Hematology Am Soc Hematol Educ Program, 2012:65-73.
  • 2Santini V, Alessandrino PE, Angelucci E, et ai. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines[J]. Leuk Res, 2010, 34(12) : 1576-1588.
  • 3Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastlc syndrome[J]. Blood, 2003, 102 (8) : 3025-3027.
  • 4Sloand EM, Wu CO, Greenberg P, et al. Factors affectin response and survival in patients with myelodysplasia treate with immuno,suppres:ive therapy[J]. J Clin Oncol, 2008, 2 (15) :2505-2511.
  • 5Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin [J]. Leukemia, 2007, 21 (7) =1436-1441.
  • 6Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome[J]. Blood, 2002,100(5) : 1570-1574.
  • 7aKadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymoeyte globulin, ciclosporin, methylprednisone, and granulocyte colony stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome[J]. Br J Hematol, 2012,157(3) :312- 320.
  • 8Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European Leukemia Net[J]. Blood, 2013,122(17) :2943-2964.
  • 9Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J]. Leukemia, 2014,28 (1) :78-87.
  • 10Garcia-Manero G, Jabbour E, Borthakur G, et al. Randomized openqabel phase lI study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes[J]. J Clin Oncol, 2013,31(20) :2548-2553.

引证文献1

二级引证文献5

中华血液学杂志
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部